What is OpiAID?
OpiAID is a data science firm dedicated to enhancing the safety and efficacy of addiction treatment. The company provides decision support technology to clinicians, aiming to improve patient retention in Medically Assisted Treatment (MAT). This focus on improving clinical outcomes also translates to additional revenue for clinics and reduced costs for payers when managing patients with opioid use disorder (OUD).
How much funding has OpiAID raised?
OpiAID has raised a total of $320K across 1 funding round:
Grant
$320K
Grant (2023): $320K with participation from National Institute on Drug Abuse
Key Investors in OpiAID
National Institute on Drug Abuse
The National Institute on Drug Abuse (NIDA) is a U.S. government research institute focused on the science of addiction and its treatment. Their investment in OpiAID highlights a commitment to advancing research and evidence-based interventions in the field of addiction medicine.
What's next for OpiAID?
With its recent strategic investment and substantial total funding, OpiAID is well-positioned for its next phase of growth. The company's focus on improving patient retention and clinical outcomes in MAT suggests a strategic expansion into broader healthcare systems and potentially further technological development to support clinicians. This late-stage funding likely signals an acceleration of its market penetration and a scaling of its operations to meet the growing demand for effective OUD treatment solutions.
See full OpiAID company page
